Vulvovagina Itch: The Gynecologist’s Perspective
Jonathan Silverberg, MD, Ph.D.
Director, Clinical Research
Director, Patch testing
Professor, Department of Dermatology
George Washington University School of Medicine and Health Sciences
Michael Marchetti, MD
Clinical Director of Dermatology Service
Memorial Sloan Kettering Cancer Center, New York, NY
Misha Rosenbach, MD
Associate Professor, Dermatology & Internal Medicine
Director, Cutaneous Sarcoidosis Clinic
University of Pennsylvania
Amy J. McMichael, MD, FAAD
Professor and Chair
Department of Dermatology
Wake Forest Baptist Medical Center
Winston-Salem, NC
Puff Puff and don’t pass on the great potential cannabinoids have to expand our current armament of therapeutics and address unmet clinical needs. Used for generations, derivatives of the cannabis plant have a storied history in traditional medicine only to be cast away in the 20th century through legislation and ultimately by being classified as a Schedule I substance. Yet, times they are a changing, and the study of this once US wide illegal drug led to the discovery of our own internal endocannabinoid system which is responsible for regulating a broad range of biological activities from sensation to inflammation. There has been an explosion in research and development targeting the skin’s inherent endocannabinoids system to combat inflammatory skin diseases. Do be caught downwind of these exciting and emerging developments!
Presenter: Adam Friedman, MD, FAAD is Professor and Chair of Dermatology and serves as Associate Residency Program Director, Director of Translational Research, and Director of the Supportive Oncodermatology Program in the Department of Dermatology at The George Washington University School of Medicine & Health Sciences.